Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
Exacerbations in chronic obstructive pulmonary disease (COPD), which tend to occur in clusters and increase with disease severity, come with high societal and economic burdens. Prevention and delay of recurrent exacerbations is an unmet and significant therapeutic need for patients with COPD. GALATH...
Published in: | International Journal of Chronic Obstructive Pulmonary Disease |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Text |
Language: | English |
Published: |
Dove
2023
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390712/ http://www.ncbi.nlm.nih.gov/pubmed/37533773 https://doi.org/10.2147/COPD.S418944 |
id |
ftpubmed:oai:pubmedcentral.nih.gov:10390712 |
---|---|
record_format |
openpolar |
spelling |
ftpubmed:oai:pubmedcentral.nih.gov:10390712 2023-08-27T04:12:19+02:00 Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis Singh, Dave Criner, Gerard J Agustí, Alvar Bafadhel, Mona Söderström, Johan Luporini Saraiva, Gabriela Song, Yue Licaj, Idlir Jison, Maria Martin, Ubaldo J Psallidas, Ioannis 2023-07-27 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390712/ http://www.ncbi.nlm.nih.gov/pubmed/37533773 https://doi.org/10.2147/COPD.S418944 en eng Dove http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390712/ http://www.ncbi.nlm.nih.gov/pubmed/37533773 http://dx.doi.org/10.2147/COPD.S418944 © 2023 Singh et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Int J Chron Obstruct Pulmon Dis Short Report Text 2023 ftpubmed https://doi.org/10.2147/COPD.S418944 2023-08-06T01:30:28Z Exacerbations in chronic obstructive pulmonary disease (COPD), which tend to occur in clusters and increase with disease severity, come with high societal and economic burdens. Prevention and delay of recurrent exacerbations is an unmet and significant therapeutic need for patients with COPD. GALATHEA (NCT02138916) and TERRANOVA (NCT02155660) were trials assessing efficacy of benralizumab in patients with frequent COPD exacerbations despite treatment. Although these studies found that benralizumab given as an add-on treatment did not significantly reduce annual rates of COPD exacerbations after 56 weeks of treatment, in the following exploratory post hoc analysis of the GALATHEA and TERRANOVA trials we identified a potential responder population in which treatment with benralizumab prevents recurrent COPD exacerbations during 30- and 90-day periods following an initial exacerbation, a vulnerable period for an exacerbation to occur. This responder population was characterized by high blood eosinophil counts and frequent previous exacerbations despite optimized triple therapy. These results highlight the importance of targeted therapies for high-risk populations and merit further research into the benefits of biologic therapies for COPD exacerbations. Text Terranova PubMed Central (PMC) International Journal of Chronic Obstructive Pulmonary Disease Volume 18 1595 1599 |
institution |
Open Polar |
collection |
PubMed Central (PMC) |
op_collection_id |
ftpubmed |
language |
English |
topic |
Short Report |
spellingShingle |
Short Report Singh, Dave Criner, Gerard J Agustí, Alvar Bafadhel, Mona Söderström, Johan Luporini Saraiva, Gabriela Song, Yue Licaj, Idlir Jison, Maria Martin, Ubaldo J Psallidas, Ioannis Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis |
topic_facet |
Short Report |
description |
Exacerbations in chronic obstructive pulmonary disease (COPD), which tend to occur in clusters and increase with disease severity, come with high societal and economic burdens. Prevention and delay of recurrent exacerbations is an unmet and significant therapeutic need for patients with COPD. GALATHEA (NCT02138916) and TERRANOVA (NCT02155660) were trials assessing efficacy of benralizumab in patients with frequent COPD exacerbations despite treatment. Although these studies found that benralizumab given as an add-on treatment did not significantly reduce annual rates of COPD exacerbations after 56 weeks of treatment, in the following exploratory post hoc analysis of the GALATHEA and TERRANOVA trials we identified a potential responder population in which treatment with benralizumab prevents recurrent COPD exacerbations during 30- and 90-day periods following an initial exacerbation, a vulnerable period for an exacerbation to occur. This responder population was characterized by high blood eosinophil counts and frequent previous exacerbations despite optimized triple therapy. These results highlight the importance of targeted therapies for high-risk populations and merit further research into the benefits of biologic therapies for COPD exacerbations. |
format |
Text |
author |
Singh, Dave Criner, Gerard J Agustí, Alvar Bafadhel, Mona Söderström, Johan Luporini Saraiva, Gabriela Song, Yue Licaj, Idlir Jison, Maria Martin, Ubaldo J Psallidas, Ioannis |
author_facet |
Singh, Dave Criner, Gerard J Agustí, Alvar Bafadhel, Mona Söderström, Johan Luporini Saraiva, Gabriela Song, Yue Licaj, Idlir Jison, Maria Martin, Ubaldo J Psallidas, Ioannis |
author_sort |
Singh, Dave |
title |
Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis |
title_short |
Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis |
title_full |
Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis |
title_fullStr |
Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis |
title_full_unstemmed |
Benralizumab Prevents Recurrent Exacerbations in Patients with Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis |
title_sort |
benralizumab prevents recurrent exacerbations in patients with chronic obstructive pulmonary disease: a post hoc analysis |
publisher |
Dove |
publishDate |
2023 |
url |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390712/ http://www.ncbi.nlm.nih.gov/pubmed/37533773 https://doi.org/10.2147/COPD.S418944 |
genre |
Terranova |
genre_facet |
Terranova |
op_source |
Int J Chron Obstruct Pulmon Dis |
op_relation |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390712/ http://www.ncbi.nlm.nih.gov/pubmed/37533773 http://dx.doi.org/10.2147/COPD.S418944 |
op_rights |
© 2023 Singh et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
op_doi |
https://doi.org/10.2147/COPD.S418944 |
container_title |
International Journal of Chronic Obstructive Pulmonary Disease |
container_volume |
Volume 18 |
container_start_page |
1595 |
op_container_end_page |
1599 |
_version_ |
1775356344375705600 |